ECOR electroCore, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-10.50
P/S
1.59
EV/EBITDA
-4.49
DCF Value
$-403.81
FCF Yield
-12.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.2%
Operating Margin
-42.0%
Net Margin
-44.1%
ROE
836.3%
ROA
-99.4%
ROIC
-379.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $9.6M | $-5.3M | $— |
| Q4 null | $9.2M | $-3.0M | $— |
| FY null | $32.0M | $-14.0M | $— |
| Q3 null | $8.7M | $-3.4M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.68
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.